https://doi.org/10.4081/reumatismo.2020.1303
Systemic lupus erythematosus and infections
Accepted: 31 August 2020
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Systemic lupus erythematosus (SLE) is an inflammatory and multi-systemic autoimmune disorder, characterized by an uncontrolled auto-reactivity of B and T lymphocytes, leading to the production of autoantibodies against self-directed antigens and tissue damage. The life expectancy in patients with SLE has improved tremendously in the last two decades, but the mortality rates still remain three times greater compared to those of the general population. Despite increased awareness and improved management, infections remain a major source of morbidity, mortality, hospitalization, and death in patients with SLE. The infections in SLE patients widely range from opportunistic to common bacterial and viral infections with typical or atypical presentations. Moreover, SLE patients exhibit an increased susceptibility to hospital-acquired infections. Factors associated with increased risk of infections include high disease activity, specific immune dysregulation, drug-induced immune deficiency, and organ failure with irreversible damage. Furthermore, immunosuppressive agents may make patients more susceptible to opportunistic infections. A big challenge faced by physicians in these patients is to distinguish between infections and flares of SLE, as infections may mimic them, leading to predicament in diagnosis and appropriate management. Immunosuppression used to treat severe flares of lupus can have catastrophic complications in patients with active infections. There is an urgent need for biomarkers to make an accurate differential diagnosis in this situation. In spite of increased understanding of SLE, many questions remain unanswered. Further research is needed to determine specific immune dysregulation underlying the increased susceptibility to specific infections, predictors of infection in SLE such as genetic markers, and biomarkers that discriminate between disease activity and active infections. Also, measures must be evaluated appropriately to prevent infections, and their complications in SLE.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- M. Colaci, D. Giuggioli, A. Manfredi, M. Sebastiani, F. Coppi, R. Rossi, C. Ferri, Aortic pulse wave velocity measurement in systemic sclerosis patients , Reumatismo: Vol. 64 No. 6 (2012)
- M. Colaci, D. Giuggioli, M. Sebastiani, A. Manfredi, F. Lumetti, F. Luppi, S. Cerri, C. Ferri, Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline , Reumatismo: Vol. 67 No. 4 (2015)
- M. Benucci, A. Damiani, F. Li Gobbi, V. Grossi, M. Infantino, A. Arena, M. Manfredi, Jaccoud’s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment , Reumatismo: Vol. 69 No. 2 (2017)
- A. Alunno, O. Bistoni, E. Bartoloni Bocci, S. Caterbi, B. Bigerna, A. Pucciarini, A. Tabarrini, R. Mannucci, D. Beghelli, B. Falini, R. Gerli, IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren’s syndrome , Reumatismo: Vol. 65 No. 4 (2013)
- F. Ceccarelli, V. Covelli, G. Olivieri, F. Natalucci, C. Alessandri, F. Conti, Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study , Reumatismo: Vol. 74 No. 2 (2022)
- A. Tincani, G. Fontana, C. Mackworth-Young, The history of antiphospholipid syndrome , Reumatismo: Vol. 74 No. 4 (2022)
- L. Cometi, P. Francesconi, B. Bellini, L. Turco, F. Voller, F. Nacci, S. Bellando-Randone, M. Matucci-Cerinic, S. Guiducci, Rheumatic diseases in migrant patients resident in Tuscany: epidemiological data analysis and single-center experience , Reumatismo: Vol. 76 No. 1 (2024)
- M. Rampudda, P. Marson, G. Pasero, The main stages in the history of systemic lupus erythematosus , Reumatismo: Vol. 61 No. 2 (2009)
- A. Fayed, M.M. El Menyawi, M. Ghanema, O. Shaker, R. Elgohary, Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study , Reumatismo: Vol. 72 No. 3 (2020)
- M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni, Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients , Reumatismo: Vol. 65 No. 6 (2013)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
